
Assessing breast MRI scans, pathology and clinical data, the AI-powered TumorSight Risk software reportedly provides five- and 10-year risk for breast cancer recurrence for women with HR+, HER2-negative stage I-IIIA breast cancer.
7 reasons why it might be time to switch from PACS to VNA.
Health system purchases of VNAs are outstripping PACS purchases by 5 times, according to presenters at HIMSS 2015 in Chicago.Presenters Trent Conwell, technical manager at Sentara Healthcare, and Eric Rice, Chief Technology Officer of Mach7 Technologies, a company that sells VNAs, highlighted the factors driving this trend.






